We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before European leaders. We also look at the reasons behind why the FDA rejected ...

The issue came down to the study design: control group participants over 65 did not receive the high-dose flu shot; instead, ...

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following the launch of its next-generation Covid vaccine ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

The Cambridge, Massachusetts-based company ​has been struggling financially as demand for ​COVID vaccines collapsed in the ⁠years ⁠following its ⁠pandemic windfall. ​It is working on newer ​products ...

Richard Hatchett, who leads the Coalition for Epidemic Preparedness Innovations, or Cepi – a partnership of governments and philanthropies that was among the first to fund COVID-19 vaccines in ...

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.

Know the symptoms of COVID-19 in children, what to do if your child appears sick and how to keep your family healthy.

It’s rare that FDA refuses to file an application, particularly for a new vaccine, which requires companies and FDA staff to engage in months or years of discussions.

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.